Ipsen S.A. (IPSEF)

117,60 0,00 (0,00%) Alla chiusura: 11:46AM EDT

Ipsen S.A.

65, quai Georges Gorse
Boulogne-Billancourt 92100
France
33 1 58 33 50 00
https://www.ipsen.com

Settore/i: Healthcare
Settore: Drug Manufacturers - Specialty & Generic
Impiegati a tempo pieno: 5.325

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. David Loew	MD, CEO & Director	2,27M	N/D	1967
Mr. Aymeric Le Chatelier	Executive VP & CFO	784,46k	N/D	1969
Dr. Aidan Murphy Ph.D.	Executive VP and Head of Technical Operations	N/D	N/D	1966
Mr. Craig Marks	Vice-President of Investor Relations	N/D	N/D	N/D
Mr. Francois Garnier	Executive VP of Legal Affairs, General Counsel & Chief Business Ethics Officer	N/D	N/D	1962
Ms. Gwenan White	Executive VP and Head of Communications, Public Affairs & Sustainability	N/D	N/D	N/D
Mr. Regis Mulot	Executive VP & Chief Human Resources Officer	N/D	N/D	1966
Ms. Dominique Bery	Head of Nordics & Baltics	N/D	N/D	1971
Mr. Bartosz Bednarz D.D.S.	Executive VP and Head of Global Product & Portfolio Strategy	N/D	N/D	N/D
Mr. Philippe Lopes-Fernandes CBO	Executive VP & Chief Business Officer	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2023 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.

Governance aziendale

L'ISS Governance QualityScore di Ipsen S.A. al 1 aprile 2024 è 7. I criteri di valutazione fondamentali sono revisione: 8; Consiglio di Amministrazione: 7; diritti degli azionisti: 7; retribuzione: 6.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.